Hey Saul fans,

I’ve been following this company with great interest.

See the first thread on this company here: http://discussion.fool.com/novocure-nvcr-32776931.aspx?sort=whol…

Q2 results looked good in absolute terms, but failed to meet expectations:


+Revenue +114% to $38.3 million (market wanted $40.4…miss)
+Active patients +64%
—US +347 patients, total 1,083
—Germany & international +221 patients, total 376
+61% prescription growth
+Net loss -48% to $21.1 ($0.24), (market wanted $0.22…miss)
+Cash balance ~$185 million
+Quarterly cash burn ~$16 milloin
+93% of private pays lives have access to Optune
+Recruting for phase 3 lung cancer trial + brain metastasis

Trial initiations:

Phase 3 pivotal trial in locally advanced pancreatic cancer (2H 2017)
Phase 3 pivotal trial in recurrent ovarian cancer (2018)

Top-line data readouts:
Phase 2 pilot STELLAR trial in mesothelioma (2018)
Phase 3 pivotal METIS trial in brain metastases (2020)
Phase 3 pivotal LUNAR trial in non-small cell lung cancer (2021)

Shares have run up recently so sell off of ~5% in early morning trading isn’t surprising given miss.